Trends in Pharmacological Sciences
ReviewTargeting of TAK1 in inflammatory disorders and cancer
Section snippets
Update and impact on TAK1 signaling
The kinase TAK1 was discovered in 1995 by Matsumoto and colleagues in a complementation screen based on a MAPK pathway in yeast and characterized as a MAPK kinase kinase (MAP3K), which is activated by TGF-β and bone morphogenetic protein (BMP) [1]. However, during the decade after the original report, TAK1 was characterized and widely accepted as a key player in pro-inflammatory cytokine signaling, including tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), and Toll-like receptor (TLR)
Emerging new functions of TAK1 in immunity
Both the NF-κB and AP-1 pathways play pivotal roles in the immune system. For example, deletion of genes encoding subunits of these transcription factors in lymphocytes and other immune cells causes several defects in the development of immune organs, including lymph nodes, and activation of acquired and innate immunity 38, 39. In addition, pharmacological interventions involving chemical inhibitors of protein kinases that regulate these transcription factors, including p38 and IKK, are
Microbial regulation of the TAK1 complex
Significant features of TAK1 in host defense are also illustrated by microbial targeting of the TAK1 complex (Figure 1). The Yersinia enterocolitica virulence factor YopP inhibits host cell NF-κB signaling by direct binding to TAB1 to synergistically potentiate the p38-mediated feedback regulation of TAK1 [57]. NleE, an enteropathogenic Escherichia coli that expresses the conserved bacterial type-III-secreted effector responsible for blocking host NF-κB signaling, interferes with the
Therapeutic intervention in inflammatory disorders
Protein kinases are promising molecular targets for therapeutic interventions. Several kinase inhibitors have been launched for the treatment of human diseases. In inflammatory signaling cascades, inhibitors of several protein kinases, including p38 and IKK, have been developed as candidates for inflammatory disorders such as rheumatoid arthritis and airway inflammation [66].
On the basis of its diverse functions, TAK1 has become one of the major target kinases in inflammatory disorders. Because
Targeting TAK1 in cancer therapy
In recent years it has become increasingly clear that the inflammatory and innate immune system plays a critical role in cancer development and progression. The tumor microenvironment is an established concept in which the relationship between chronic inflammation and cancer or the contribution of the stroma to tumor progression influences the development of pre-metastatic niches and the shaping of genetic signatures of metastatic cells. Deficiency of either Itch or CYLD, essential ubiquitin
Prospective strategies for targeting TAK1
As described above, systemic administration of selective chemical TAK1 inhibitors showed significant anti-inflammatory and anti tumor activities in animal models; however, the fact that TAK1 has diverse cellular functions increases the risk of adverse effects, especially susceptibility to bacterial and viral infections. It was recently reported that systemic TAK1–siRNA lipoplex delivery alleviates inflammation in experimental autoimmune arthritis with decreased frequency of Th1 and Th17 cells
Concluding remarks
As summarized in this review, TAK1 is now an attractive molecular target for the treatment of several human diseases; however, this possibility is mainly based on findings for cultured cells in vitro and loss-of-function studies in vivo. Information on where and when TAK1 is activated in injured tissues is completely lacking; therefore, establishment of immunohistochemistry for activated TAK1 will provide new information about its pathophysiological functions. Undesirable effects must also be
Acknowledgments
This work was supported in part by Grants-in-Aid for Scientific Research on Innovative Areas and Scientific Research (C) from the Ministry of Education, Culture, Sports, Science and Technology, Japan, and grants from the Naito Memorial Foundation.
References (93)
TAK1 mediates the ceramide signaling to stress-activated protein kinase/c-Jun N-terminal kinase
J. Biol. Chem.
(1997)TGF-β-activated kinase 1 stimulates NF-κB activation by an NF-κB-inducing kinase-independent mechanism
Biochem. Biophys. Res. Commun.
(1998)Functional interactions of transforming growth factor β-activated kinase 1 with IκB kinases to stimulate NF-κB activation
J. Biol. Chem.
(1999)TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-β
Mol. Cell
(2008)The TAK1–TRAF6 signalling pathway
Int. J. Biochem. Cell Biol.
(2010)TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway
Mol. Cell
(2000)Critical roles of threonine 187 phosphorylation in cellular stress-induced rapid and transient activation of transforming growth factor-β-activated kinase 1 (TAK1) in a signaling complex containing TAK1-binding protein TAB1 and TAB2
J. Biol. Chem.
(2005)Phosphorylation of Thr-178 and Thr-184 in the TAK1 T-loop is required for interleukin (IL)-1-mediated optimal NFκB and AP-1 activation as well as IL-6 gene expression
J. Biol. Chem.
(2008)- et al.
LUBAC, a novel ubiquitin ligase for linear ubiquitination, is crucial for inflammation and immune responses
Microbes Infect.
(2012) Lysine 63-linked polyubiquitination of TAK1 at lysine 158 is required for tumor necrosis factor α- and interleukin-1β-induced IKK/NF-κB and JNK/AP-1 activation
J. Biol. Chem.
(2010)
Protein phosphatase 6 down-regulates TAK1 kinase activation in the IL-1 signaling pathway
J. Biol. Chem.
Lys(48)-linked TAK1 polyubiquitination at lysine-72 downregulates TNFα-induced NF-κB activation via mediating TAK1 degradation
Cell. Signal.
A cytoplasmic ATM–TRAF6–cIAP1 module links nuclear DNA damage signaling to ubiquitin-mediated NF-κB activation
Mol. Cell
ATM- and NEMO-dependent ELKS ubiquitination coordinates TAK1-mediated IKK activation in response to genotoxic stress
Mol. Cell
TAK1 lysine 158 is required for TGF-β-induced TRAF6-mediated Smad-independent IKK/NF-κB and JNK/AP-1 activation
Cell. Signal.
Transforming growth factor-β (TGF-β1) activates TAK1 via TAB1-mediated autophosphorylation, independent of TGF-β receptor kinase activity in mesangial cells
J. Biol. Chem.
The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes
Mol. Cell
A critical role of TAK1 in B-cell receptor-mediated nuclear factor κB activation
Blood
The deubiquitinase CYLD targets Smad7 protein to regulate transforming growth factor β (TGF-β) signaling and the development of regulatory T cells
J. Biol. Chem.
TRAF6 inhibits Th17 differentiation and TGF-beta-mediated suppression of IL-2
Blood
Toll-like receptors and their crosstalk with other innate receptors in infection and immunity
Immunity
Transforming growth factor-β-activated kinase 1 regulates natural killer cell-mediated cytotoxicity and cytokine production
J. Biol. Chem.
Constitutive activation of TAK1 by HTLV-1 Tax-dependent overexpression of TAB2 induces activation of JNK–ATF2 but not IKK–NF-κB
J. Biol. Chem.
The cytoplasmic domain of the HIV-1 glycoprotein gp41 induces NF-κB activation through TGF-β-activated kinase 1
Cell Host Microbe
Kinase inhibitors and airway inflammation
Eur. J. Pharmacol.
A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase
J. Biol. Chem.
Oxindole derivatives as inhibitors of TAK1 kinase
Bioorg. Med. Chem. Lett.
TAK1-TAB1 fusion protein: a novel constitutively active mitogen-activated protein kinase kinase kinase that stimulates AP-1 and NF-κB signaling pathways
Biochem. Biophys. Res. Commun.
Structural basis for the interaction of TAK1 kinase with its activating protein TAB1
J. Mol. Biol.
Oncogenic Ras diverts a host TNF tumor suppressor activity into tumor promoter
Dev. Cell
TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers
Cell
In vivo RNAi-mediated silencing of TAK1 decreases inflammatory Th1 and Th17 cells through targeting of myeloid cells
Blood
TAK1 suppresses a NEMO-dependent but NF-κB-independent pathway to liver cancer
Cancer Cell
TAK1 is a master regulator of epidermal homeostasis involving skin inflammation and apoptosis
J. Biol. Chem.
Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction
Science
The kinase TAK1 can activate the NIK-IκB as well as the MAP kinase cascade in the IL-1 signalling pathway
Nature
The type I TGF-β receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner
Nat. Cell Biol.
Two mechanistically and temporally distinct NF-κB activation pathways in IL-1 signaling
Sci. Signal.
TAB1: an activator of the TAK1 MAPKKK in TGF-β signal transduction
Science
Role of the TAB2-related protein TAB3 in IL-1 and TNF signaling
EMBO J.
Essential function for the kinase TAK1 in innate and adaptive immune responses
Nat. Immunol.
TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo
Genes Dev.
Targeted disruption of the Tab1 gene causes embryonic lethality and defects in cardiovascular and lung morphogenesis
Mech. Dev.
TAB2 is essential for prevention of apoptosis in fetal liver but not for interleukin-1 signaling
Mol. Cell. Biol.
O-GlcNAcylation of TAB1 modulates TAK1-mediated cytokine release
EMBO J.
Ubiquitination in signaling to and activation of IKK
Immunol. Rev.
Cited by (296)
TAK1 is an essential kinase for STING trafficking
2023, Molecular CellPSMD13 inhibits NF-κB pathway by targeting TAK1 for K63-linked ubiquitination in miiuy croaker (Miichthys miiuy)
2023, Fish and Shellfish ImmunologyCellular stress induces non-canonical activation of the receptor tyrosine kinase EphA2 through the p38-MK2-RSK signaling pathway
2023, Journal of Biological ChemistryThe Ninj1/Dusp1 Axis Contributes to Liver Ischemia Reperfusion Injury by Regulating Macrophage Activation and Neutrophil Infiltration
2023, Cellular and Molecular Gastroenterology and Hepatology